Benzinga's Top Pre-Market Losers
May 10, 2013 at 08:33 AM EDT
Pain Therapeutics Inc. (NASDAQ: PTIE ) dipped 45.01% to $5.32 in the pre-market session after the company CEO revealed a letter from Pfizer (NYSE: PFE ) of reassessing its endorsement of the Remoxy program. Santarus, Inc. (NASDAQ: SNTS ) shares fell 6.09% to $20.20 in the pre-market trading
